Hanmi Pharm (KRX:128940) reported third-quarter net income attributable to shareholders of the parent company of 31 billion won, down 43.3% from 54.7 billion won a year earlier.
Sales for the quarter ended September was 362.1 billion won, declining 0.7% from 364.61 billion won in the year-ago period.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。